Swiss dental start-up Odne has closed its Series A1 financing round, securing SFr4.8m ($5.5m) to support its forthcoming US market launch.
The A1 round was led by independent venture fund Revere Partner and NV Capital, a family-owned venture capital boutique.
Related: Sooma raises $5.5M for depression-treating neuromod
The round also saw participation from several funds, including Dental Innovation Alliance (DIA), Plug&Play, Hatcher and Züricher Kantonalbank, as well as various family offices and angel investors.
These companies are committed to supporting Odne’s entry into the US market.
Onde CEO and co-founder Dr Andreas Schmocker said: “With over 15 million root canal treatments per year, the US is the biggest market worldwide and our number one focus. Currently, we are performing a Priority Access Program to deepen the use of our products with selected US key opinion leaders.
“At the annual meeting of the American Association of Endodontists (AAE) in April, in Los Angeles, we will introduce the Odne RPT workflow solution to the endodontic community.”
Revere Partners managing partner Dr Jeremy Krell said: “Odne is within the core investment focus of Revere Partners: innovations in oral health. After receiving FDA clearance for OdneCure and OdneFill in 2023 the Series A1 financing fuels Odne`s US market launch to the endodontic community.
“Together with all investors, Revere Partners is proud to elevate Odne’s RPT workflow for the benefit of patients, endodontists, and the referring general dentists.”
Odne’s new technology platform for root preservation therapy (RPT) is anticipated to transform the field of endodontics.
The company’s RPT workflow introduces three new medical devices that facilitate minimally invasive root canal cleaning as well as light-cured obturation.
The RPT technology developed by Odne not only reduces the need for bleach but also increases the speed of endodontic therapy.
This approach has been designed to enhance patient safety and comfort while focusing on preserving tooth structures for better long-term treatment outcomes.
In January 2024, DIA invested in Odne, which was previously known as Lumendo.
